USE OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND PACAP ANALOGS AS ADJUNCTIVE TREATMENTS WITH INHIBITORS OF CALCINEURIN OR INHIBITORS OF THE MAMMALIAN TARGET OF RAPAMYCIN (mTOR) COMPLEXES
Номер патента: US20120309683A1. Автор: Batuman Vecihi, Coy David H., Li Min, Maderdrut Jerome L.. Владелец: The Administrators of the Tulane Educational Fund. Дата публикации: 06-12-2012.This invention relates to methods and compositions for the treatment, management, reduction, or prevention of injuries to one or more major organs of the body, e.g., the brain, heart, lung, kidneys, liver, and gastrointestinal tract, of a mammal (e.g., a human) caused by one or more calcineurin or mammalian target of rapamycin (mTOR) complex inhibitors. The methods include administering an effective amount of one or more pituitary adenylate cyclase-activating polypeptide (PACAP)-like compounds to the mammal. Combination therapy with one or more PACAP-like compounds, either alone or in combination with one or more other prophylactic/therapeutic agents, plus one or more inhibitors of either calcineurin or the mTOR complexes can be used to treat organ transplantation, autoimmune diseases, graft-versus-host disease, Behçet's disease, hematological cancers, noninfectious uveitis, sarcoidosis, tuberous sclerosis complex, acute neurological diseases, age-related neurodegenerative diseases, Huntington's disease and other CAG codon repeat expansion diseases, keratoconjunctivitis sicca, and restenosis. 1. A method for treating , managing , or reducing an injury to one or more major organs of the body of a mammal resulting from administration of one or more of a calcineurin inhibitor , a mammalian target of rapamycin (mTOR) inhibitor , or a tyrosine kinase inhibitor to said mammal , said method comprising administering to said mammal an effective amount of at least one pituitary adenylate cyclase-activating polypeptide (PACAP)-like compound.2. The method of claim 1 , wherein said PACAP-like compound comprises a polypeptide sequence having at least 90% sequence identity to a sequence selected from SEQ ID NOs: 1 to 72.3. The method of or claim 1 , wherein said PACAP-like compound comprises a polypeptide sequence having at least 95% sequence identity to a sequence selected from SEQ ID NOs: 1 to 72.4. The method of any one of to claim 1 , wherein said PACAP-like compound comprises ...